<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854658</url>
  </required_header>
  <id_info>
    <org_study_id>PT003007-00</org_study_id>
    <nct_id>NCT01854658</nct_id>
  </id_info>
  <brief_title>Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)</brief_title>
  <official_title>A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks),
      placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and
      Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001),
      and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1</measure>
    <time_frame>At Week 24</time_frame>
    <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</measure>
    <time_frame>Over 24 weeks</time_frame>
    <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>At week 24</time_frame>
    <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George Respiratory Questionnaire (SGRQ) Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Ventolin HFA Use</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Action as Assessed by FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1615</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FF MDI administered as two puffs BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI administered as two puffs BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GFF MDI administered as two puffs BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo administered as two puffs BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT003)</intervention_name>
    <description>GFF MDI administered as two puffs BID</description>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <other_name>glycopyrrolate/formoterol fumarate metered-dose inhaler</other_name>
    <other_name>(GFF MDI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP MDI (PT001)</intervention_name>
    <description>GP MDI administered as two puffs BID</description>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
    <other_name>glycopyrrolate metered dose inhaler (GP MDI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI (PT005)</intervention_name>
    <description>FF MDI administered as two puffs BID</description>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
    <other_name>formoterol fumarate metered dose inhaler (FF MDI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female subjects at least 40 years of age and no older than 80 at Visit 1.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

          -  Subjects with FEV1/FVC ratio of &lt;0.70 and FEV1 &lt;80% predicted normal and ≥750 mL if
             FEV1 &lt;30% of predicted normal value.

          -  Subjects willing and, in the opinion of the investigator, able to adjust current COPD
             therapy as required by the protocol

        Key Exclusion Criteria:

          -  Significant diseases other than COPD, i.e. disease or condition which, in the opinion
             of the investigator, may put the patient at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study

          -  Current diagnosis of asthma or alpha-1 antitrypsin deficiency

          -  Other active pulmonary disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary
             pulmonary hypertension, or uncontrolled sleep apnea

          -  Hospitalized due to poorly controlled COPD within 3 months prior to screening or
             during the Screening Period

          -  Poorly controlled COPD, defined as acute worsening of COPD that requires treatment
             with oral corticosteroids or antibiotics within 6 weeks prior to screening or during
             the Screening Period

          -  Lower respiratory tract infections that required antibiotics within 6 weeks prior to
             screening or during the Screening Period

          -  Unstable ischemic heart disease, left ventricular failure, or documented myocardial
             infarction within 12 months of enrollment.

          -  Recent history of acute coronary syndrome, percutaneous coronary intervention,
             coronary artery bypass graft within the past three months

          -  Congestive heart failure (CHF NYHA Class III/IV)

          -  Clinically significant abnormal 12-lead ECG

          -  Abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times
             upper limit of normal at Visit 1 and on repeat testing

          -  Cancer not in complete remission for at least five years

          -  History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
             anticholinergics, lactose/milk protein or any component of the MDI

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>u</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Elk Grove</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Siteq</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cedar Knolls</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ricmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bridgeport</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4151&amp;filename=PT003007-02%20Protocol%20Amendment-FINAL-11Sept14_29June16_Redacted.pdf</url>
    <description>PT003007-02 Protocol Amendment-FINAL-Redacted.pdf</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>May 21, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <disposition_first_submitted>July 7, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 30, 2015</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 140 sites throughout the United States from July 2013 - February 2015. Study participation was a maximum of 32 weeks.</recruitment_details>
      <pre_assignment_details>A multicenter, randomized, double-blind, parallel group, chronic dosing, active- and placebo-controlled study; each participant was randomized to receive 1 of 4 possible treatments over the course of a 24-week treatment period (With a randomization of 7:6:6:3 GFF MDI, GP MDI, FF MDI and Placebo MDI)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="P2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg administered as two puffs BID</description>
        </group>
        <group group_id="P3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="P4">
          <title>Placebo MDI</title>
          <description>Inhaled placebo administered as two puffs BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="439"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="512"/>
                <participants group_id="P4" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="365"/>
                <participants group_id="P3" count="432"/>
                <participants group_id="P4" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 subjects participated in more than one Phase 3 Pearl study (a protocol violation) and had overlapping treatment exposure - these subjects were removed from the ITT and safety populations;
1 subject participated in more than one Phase 3 Pearl study but did not have overlapping treatment exposure - this subject was removed from the ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="B2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg administered as two puffs BID</description>
        </group>
        <group group_id="B3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="B4">
          <title>Placebo MDI</title>
          <description>Inhaled placebo administered as two puffs BID</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="437"/>
            <count group_id="B2" value="439"/>
            <count group_id="B3" value="510"/>
            <count group_id="B4" value="223"/>
            <count group_id="B5" value="1609"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" spread="7.8"/>
                    <measurement group_id="B2" value="62.8" spread="8.4"/>
                    <measurement group_id="B3" value="62.8" spread="8.2"/>
                    <measurement group_id="B4" value="64.2" spread="8.7"/>
                    <measurement group_id="B5" value="62.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="723"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="272"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
        <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.</description>
        <time_frame>At Week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1</title>
          <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="367"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" lower_limit="0.039" upper_limit="0.082"/>
                    <measurement group_id="O2" value="0.063" lower_limit="0.041" upper_limit="0.084"/>
                    <measurement group_id="O3" value="0.116" lower_limit="0.097" upper_limit="0.136"/>
                    <measurement group_id="O4" value="0.013" lower_limit="-0.018" upper_limit="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</title>
        <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
        <time_frame>Over 24 weeks</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks</title>
          <description>Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="434"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="503"/>
                <count group_id="O4" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" lower_limit="0.064" upper_limit="0.095"/>
                    <measurement group_id="O2" value="0.082" lower_limit="0.067" upper_limit="0.097"/>
                    <measurement group_id="O3" value="0.137" lower_limit="0.123" upper_limit="0.151"/>
                    <measurement group_id="O4" value="0.008" lower_limit="-0.014" upper_limit="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1</title>
        <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24</description>
        <time_frame>At week 24</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1</title>
          <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="431"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.268" lower_limit="0.244" upper_limit="0.292"/>
                    <measurement group_id="O2" value="0.223" lower_limit="0.199" upper_limit="0.247"/>
                    <measurement group_id="O3" value="0.350" lower_limit="0.328" upper_limit="0.371"/>
                    <measurement group_id="O4" value="0.083" lower_limit="0.048" upper_limit="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St. George Respiratory Questionnaire (SGRQ) Score</title>
        <description>Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>St. George Respiratory Questionnaire (SGRQ) Score</title>
          <description>Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="362"/>
                <count group_id="O3" value="430"/>
                <count group_id="O4" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-3.5" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-3.4" upper_limit="-1.0"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-4.1" upper_limit="-1.8"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-3.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Ventolin HFA Use</title>
        <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Ventolin HFA Use</title>
          <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Puffs / Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="438"/>
                <count group_id="O3" value="510"/>
                <count group_id="O4" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-0.9" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-0.6" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-1.2" upper_limit="-0.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Action as Assessed by FEV1</title>
        <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
        <time_frame>Day 1</time_frame>
        <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Inhaled placebo administered as two puffs BID</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Action as Assessed by FEV1</title>
          <description>Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant</description>
          <population>Intent-to-Treat population with evaluable data (no imputation) for this outcome measure.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="429"/>
                <count group_id="O4" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" lower_limit="0.163" upper_limit="0.188"/>
                    <measurement group_id="O2" value="0.052" lower_limit="0.040" upper_limit="0.065"/>
                    <measurement group_id="O3" value="0.192" lower_limit="0.180" upper_limit="0.204"/>
                    <measurement group_id="O4" value="0.006" lower_limit="-0.012" upper_limit="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.212" lower_limit="0.199" upper_limit="0.225"/>
                    <measurement group_id="O2" value="0.109" lower_limit="0.096" upper_limit="0.122"/>
                    <measurement group_id="O3" value="0.237" lower_limit="0.225" upper_limit="0.249"/>
                    <measurement group_id="O4" value="0.022" lower_limit="0.003" upper_limit="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 5 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At 15 min post dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and Serious Adverse Events (SAEs) will be collected from the time the subject signs the informed consent form up to 14 days following the last dose of study drug.</time_frame>
      <desc>Safety population included all participants who were administered investigational drug; participants were included in safety population according to the investigational drug received</desc>
      <group_list>
        <group group_id="E1">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="E2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg administered as two puffs BID</description>
        </group>
        <group group_id="E3">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg administered as two puffs BID</description>
        </group>
        <group group_id="E4">
          <title>Placebo MDI</title>
          <description>Inhaled placebo administered as two puffs BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="510"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="438"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="439"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="438"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="439"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="510"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="438"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="439"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="510"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="438"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="439"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="510"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

